We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
+32.57%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$628M
AUM Growth
+$187M
(+42%)
Cap. Flow
+$205M
Cap. Flow
% of AUM
32.59%
Top 10 Holdings %
Top 10 Hldgs %
40.48%
Holding
169
New
52
Increased
19
Reduced
22
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLRN
ACELYRIN
SLRN
|
+$59.7M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$10.3M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$10.1M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$9.47M |
| 5 |
Disc Medicine
IRON
|
+$8.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunovant
IMVT
|
+$14.4M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$13.5M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$7.11M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
+$6.37M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$5.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLRN
1
DELISTED
ACELYRIN
SLRN
| $61M | 9.71% |
+2,918,426
| New | +$59.7M |
|
2
PUT
argenx
ARGX
$57.8B
| $51.5M | 8.2% |
+132,100
| New | +$52M |
|
3
CALL
BridgeBio Pharma
BBIO
$16.2B
| $21.2M | 3.37% |
1,229,800
+680,200
| +124% | +$10.2M |
|
4
CALL
Biomea Fusion
BMEA
$91.1M
| $20.6M | 3.27% |
936,800
+645,800
| +222% | +$20.2M |
|
5
CALL
TG Therapeutics
TGTX
$8.5B
| $20.5M | 3.27% |
+826,100
| New | +$21.3M |
|
|
6
PUT
TG Therapeutics
TGTX
$8.5B
| $20.5M | 3.27% |
+826,100
| New | +$21.3M |
|
7
CALL
AstraZeneca
AZN
$261B
| $17.9M | 2.85% |
+125,000
| New | +$18.4M |
|
|
8
CALL
argenx
ARGX
$57.8B
| $14.8M | 2.36% |
+38,000
| New | +$14.9M |
|
9
PUT
Sarepta Therapeutics
SRPT
$1.68B
| $14M | 2.23% |
122,100
-149,200
| -55% | -$19.2M |
|
|
VTYX
10
PUT
DELISTED
Ventyx Biosciences
VTYX
| $12.3M | 1.95% |
+374,100
| New | +$12.9M |
|
|
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
| $12.2M | 1.94% |
133,800
+33,800
| +34% | +$2.92M |
|
|
APLS
12
PUT
DELISTED
Apellis Pharmaceuticals
APLS
| $12.1M | 1.93% |
+133,000
| New | +$11.5M |
|
13
Merck
MRK
$322B
| $11.5M | 1.84% |
100,000
| – | – |
|
|
14
IDEAYA Biosciences
IDYA
$3.49B
| $11.5M | 1.84% |
+490,893
| New | +$10.1M |
|
|
NUVL
15
DELISTED
Nuvalent
NUVL
| $11.5M | 1.83% |
+272,752
| New | +$10.3M |
|
16
CALL
CRISPR Therapeutics
CRSP
$4.68B
| $11.2M | 1.79% |
+200,000
| New | +$11.3M |
|
|
17
PUT
CRISPR Therapeutics
CRSP
$4.68B
| $11.2M | 1.79% |
+200,000
| New | +$11.3M |
|
|
RETA
18
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.2M | 1.79% |
110,000
+10,000
| +10% | +$946K |
|
|
19
Disc Medicine
IRON
$2.9B
| $10.7M | 1.7% |
+240,031
| New | +$8.52M |
|
20
Insmed
INSM
$23.3B
| $10.2M | 1.63% |
485,000
| – | – |
|
21
Biohaven
BHVN
$2.21B
| $10.2M | 1.63% |
427,417
+25,091
| +6% | +$432K |
|
22
PUT
BioMarin Pharmaceuticals
BMRN
$11.4B
| $8.67M | 1.38% |
+100,000
| New | +$9.41M |
|
|
23
Crinetics Pharmaceuticals
CRNX
$8.85B
| $8.56M | 1.36% |
+475,000
| New | +$9.47M |
|
|
IMGN
24
DELISTED
Immunogen Inc
IMGN
| $8.45M | 1.35% |
+447,700
| New | +$5.29M |
|
25
PUT
Aclaris Therapeutics
ACRS
$765M
| $8.26M | 1.32% |
796,300
+64,300
| +9% | +$582K |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Ikarian Capital held 169 positions worth $628M, up 42% from $441M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Ikarian Capital deployed $205M of net new capital in Q2 2023, opening 52 new positions and adding to 19 existing holdings. Its largest new stake was ACELYRIN: 2,918,426 shares worth $61M.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 53% a quarter earlier.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $7.11M trimmed.
- Ikarian Capital's largest Q2 2023 buy was ACELYRIN: 2,918,426 shares worth $61M.
- Ikarian Capital added most to Apellis Pharmaceuticals in Q2 2023, an estimated $2.92M increase.
- Ikarian Capital's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $7.11M.
- Ikarian Capital fully exited Immunovant in Q2 2023, selling an estimated $14.4M.
- Ikarian Capital's ten largest holdings make up 40% of its $628M portfolio in Q2 2023.
- Ikarian Capital opened 52 new positions and closed 47 in Q2 2023.
- Ikarian Capital's portfolio value rose 42% quarter-over-quarter to $628M.
Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.